title: Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis.
authors.forename: T N
authors.initials: TN
authors.lastname: Duffy
authors.forename: M
authors.initials: M
authors.lastname: Genta
authors.forename: S
authors.initials: S
authors.lastname: Moll
authors.forename: P-Y
authors.initials: PY
authors.lastname: Martin
authors.forename: C
authors.initials: C
authors.lastname: Gabay
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D006801:Humans; D011695:IgA Vasculitis / Q000139:chemically induced* / Q000473:pathology; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000037:antagonists & inhibitors; D014657:Vasculitis / Q000473:pathology
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept